Maintenance of normal sinus rhythm with antiarrhythmic drugs

Atrial Fibrillation

Volumn , Issue , 2004, Pages 195-217

  Reiffel, James A ^a  

^a New York Presbyterian Hospital ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 27144467640     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (68)

1. Fuster V, Ryden LE, Asinger RW, et al. Practice Guidelines, European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients with Atrial Fibrillation). North American Society of Pacing and Electrophysiology. ACC/AHA/ESC Guidelines for the Management of Patients with Atrial Fibrillation: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients with Atrial Fibrillation) Developed in Collaboration with the North American Society of Pacing and Electrophysiology. Circulation 2001; 104(17):2118— 2150.
2. Sager PT, Behboodikhah M. Frequency-dependent electrophysiologic effects of D, L-sotalol and quinidine and modulation by beta-adrenergic stimulation. J Cardiovasc Electrophysiol 1996; 7:102–112.
3. Crijns HJ, Van Gelder IC, Van Gilst WH, et al. Serial antiarrhythmic drug treatment to maintain sinus rhythm after electrical cardioversion for chronic atrial fibrillation or atrial flutter. Am J Cardiol 1991; 68:335–341.
4. Juul-Moller S, Edvardsson AN, Rehnqvist-Ahlberg N. Sotalol versus quinidine for the maintenance of sinus rhythm after direct current conversion of atrial fibrillation. Circulation 1990; 82:1932–1939.
5. Boissel JP, Wolfe E, Gillet J, et al. Controlled trial of a long-acting quinidine for maintenance of sinus rhythm after conversion of sustained atrial fibrillation. Eur Heart J 1981; 2:49–55.
6. Sodermark T, Yansson B, Olson A, et al. Effect of quinidine on maintaining sinus rhythm after cardioversion of atrial fibrillation or flutter. A multicenter study from Stockholm. Br Heart J 1975; 37:486–492.
7. Hillestadt L, Bjerkerlund C, Dale J, et al. Quinidine in maintenance of sinus rhythm after electroversion of chronic atrial fibrillation. A control study. Br Heart J 1971; 33:518–521.
8. Grande P, Sonne B, Pedersen A. A controlled study of digoxin and quinidine in patients DC reverted from atrial fibrillation to sinus rhythm. Circulation 1986; 74:II-101.
9. Lloyd EA, Gersh BJ, Forman R. The efficacy of quinidine and disopyramide in the maintenance of sinus rhythm after electroversion from atrial fibrillation: a double-blind study comparing quinidine, disopyramide, and placebo. S Afr Med J 1984; 65, 367–369.
10. Zehender M, Hohnloser S, Muller B. Effects of amiodarone versus quinidine and verapamil in patients with chronic atrial fibrillation: results of a comparative study and 2-year follow up. J Am Cardiol 1992; 19:1054–1059.
11. Rasmussen K, Andersen A, Abrahamsen A, et al. Flecainide versus diso- pyramide in maintaining sinus rhythm following conversion of chronic atrial fibrillation. Eur Heart J 1998; 9:1–52.
12. Karlson BW, Torstensson I, Abjorn C, Jansson SO, Peterson LE. Disopyr- amide in the maintenance of sinus rhythm after electroversion of atrial fibrillation. A placebo-controlled one-year follow up study. Eur Heart J 1988; 9:284–290.
13. Crjns HJGM, Gooselink ATM, Lie KI. Propafenone versus disopyramide for the maintenance of sinus rhythm after electrical cardioversion of atrial fibrillation: a randomized double-blind study. Cardiovasc Drugs Ther 1996; 2:145152.
14. Reimold SC, Cantillon CO, Friedman PL, Antman EN. Propafenone versus sotalol for suppression of recurrent symptomatic atrial fibrillation. Am J Cardiol 1993; 71:558–563.
15. Antman EM, Beamer AD, Cantillon C, McGowan N, Goldman L, Friedman P. Long-term oral propafenone therapy for suppression of refractory symptomatic atrial fibrillation and atrial flutter. J Am Coll Cardiol 1988; 12:1011–1018.
16. Van Gelder JC, Crijns HJ, Van Gilst WH, Van Wijk LM, Lie KI. Efficacy and safety of flecainide acetate in the maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation or atrial flutter. Am J Cardiol 1989; 64:1317–1321.
17. Zarembski DG, Nolan PE, Slack MD, Caruso AC. Treatment of resistant atrial fibrillation. A meta-analysis comparing amiodarone and flecainide. Arch Intern Med 1995; 155:1885–1891.
18. Chun SG, Sager PT, Stevenson WG, Nadamanee K, Middelkauff HR, Singh BN. Long-term efficacy of amiodarone for maintenance of normal sinus rhythm in patients with refractory atrial fibrillation or flutter. Am J Cardiol 1995; 76:47–50.
19. Gold RL, Haffajee CI, Charos G, Sloan K, Baker S, Alpert JS. Amiodarone for refractory atrial fibrillation. Am J Cardiol 1986; 57:124–127.
20. Szyszka A, Paluszkiewicz P, Baszynska H. Prophylactic treatment after electroconversion of atrial fibrillation in patients after cardiac surgery—a controlled two year follow up study. J Am Coll Cardiol 1993; 21:A-201.
21. Middlekauff HR, Wiener I, Stevenson WG. Low-dose amiodarone for atrial fibrillation. Am J Cardiol 1993; 71(suppl):75F-81F.
22. Anderson JL. Long-term safety and efficacy of flecainide in the treatment of supraventricular tachyarrhythmias: the United States experience. Am J Cardiol 1992; 70(suppl):11A-18A.
23. Chiemienti M, Cullen MT, Casadei G, for the Flecainide and Propafenone Italian Study (FAPIS) Investigators. Safety of long-term flecainide and propafenone in the management of patients with symptomatic paroxysmal atrial fibrillation: report from the flecainide and propafenone Italian study investigators. Am J Cardiol 1996; 77(suppl):60A-65A.
24. Aliot E, Denjoy I, and the Flecainide AF French Study Group. Comparison of the safety and efficacy of flecainide versus propafenone in hospital out-patients with symptomatic atrial fibrillation/flutter. Am J Cardiol 1996; 77(suppl):66A- 71A.
25. Naccarelli GV, Dorian P, Hohnloser SH, Coumel P, for the Flecainide Multicenter Atrial Fibrillation Study Group. Prospective comparison of flecainide versus quinidine for the treatment of paroxysmal atrial fibrillation/flutter. Am J Cardiol 1996; 77(suppl):53A-59A.
26. Bellandi F, Dabizzi RP, Niccoli L, Cantini F, Palchetti R. Propafenone and sotalol: long term efficacy and tolerability in the prevention of paroxysmal atrial fibrillation. A placebo-controlled double-blind study. G Ital Cardiol 1996; 26:379–390.
27. Anderson JL, Gilbert EM, Alpert BL, Henthorn RW, Waldo AL, Bhandari AK, Hawkinson RW, Prichett EL. Prevention of symptomatic recurrences of paroxysmal atrial fibrillation in patients initially tolerating antiarrhythmic therapy: a multicenter, double-blind, crossover study of flecainide and placebo. Circulation 1989; 80:1557–1570.
28. Richiardi E, Gaita F, Greco C, Gaschino G, Comb Costa G, Rosettani E, Brusc A. Propafenone versus hydroquinidine in long-term pharmacological prophylaxis of atrial fibrillation. Cardiologica 1992; 37:123–127.
29. Lee SH, Chen SA, Chiang CE, Tai CT, Wen ZC, Wang SP, Chang MS. Comparison of oral propafenone and quinidine as an initial treatment option in patients with symptomatic paroxysmal atrial fibrillation: a double-blind, randomized trial. J Intern Med 1996; 239:253–260.
30. Clementy J, Dulhoste MN, Laiter C, Denjoy I, Dos Santos P. Flecainide acetate in the prevention of paroxysmal atrial fibrillation: a nine month follow up of more than 500 patients. Am J Cardiol 1992; 79(suppl):44A-49A.
31. Sonnhag C, Kallryd A, Nylander E, Ryden L. Long term efficacy of flecainide in paroxysmal atrial fibrillation. Acta Med Scand 1988; 224:563–569.
32. Hammill SC, Wood DL, Gersh BJ, Osborn MJ, Holmes DR Jr. Propafenone for paroxysmal atrial fibrillation. Am J Cardiol 1988; 61:473–474.
33. Leclerca JF, Chouty F, Denjoy J, Coumel P, Slama R. Flecainide in quinidine resistant atrial fibrillation. Am J Cardiol 1992; 70(suppl):62A-65A.
34. Anderson JL, Platt ML, Guarnieri T, Fox TL, Maser MJ, Prichet EL. Flecainide acetate for paroxysmal supraventricular tachycardias. Am J Cardiol 1994; 74:578–584.
35. Singh SN, Zoble RG, Yellen L, et al. Efficacy and safety of oral dofetilide; in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation/flutter: the symptomatic atrial fibrillation investigative research on dofetilide (sAFIRE-D) study. Circulation 2000; 102:2385–2390.
36. Greenbaum R, Campbell TJ, Channer KS, et al. Conversion of atrial fibrillation and maintenance of sinus rhythm by dofetilide. the EMERALD (European and Australian Multicenter Evaluative Research of Atrial Fibrillation Dofetilide) study [abstr]. Circulation 1998; 98(suppl I):1–633.
37. Benditt DG, Williams HH, Jin J, et al. Maintenance of sinus rhythm with oral D, L-sotalol in patients with symptomatic atrial fibrillation and/or atrial flutter. Am J Cardiol 1999; 84:270–277.
38. Pritchett EL, Page RL, Connolly SJ, Marcello SR, Schnell DJ, Wilkinson WE. Antiarrhythmic effects of azimilide in atrial fibrillation: efficacy and dose- response. J Am Coll Cardiol 2000; 36:794–802.
39. Stroobandt R, Stiels B, Hoebrechts R, et al. Propafenone for conversion and prophylaxis of atrial fibrillation. Am J Cardiol 1997; 79:418–423.
40. Wanless RS, Anderson K, Joy M, et al. Multicenter comparative study of the efficacy and safety of sotalol in the prophylactic treatment of patients with paroxysmal supraventricular tachyarrhythmias. Am Heart J 1997; 133:441–446.
41. Reiffel JA. Selecting an antiarrhythmic agent for atrial fibrillation should be a patient-specific data-driven decision. Am J Cardiol 1998; 82:72N-81N.
42. Reiffel JA, Camm AJ, Haffajee CJ, et al. International consensus roundtable on atrial fibrillation. Cardiol Rev 2000; 12(suppl):1–19.
43. Roy D, Talajic M, Dorian P, et al. Amiodarone to prevent recurrence of atrial fibrillation. N Eng J Med 2000; 342:913–920.
44. Leenhardt A, Thomas O, Coumel P. Pharmacological treatment of atrial fibrillation. Arch Malad Coeur Vaisseaux 1997; 90:41–46.
45. Louis A, Cleland JG, Crabbe S, Ford S, Thackray S, Houghton T, Clark A. CAPRICORN, COPERNICUS, MIRACLE, STAF, RITZ-2, RECOVER and RENAISSANCE and cachexia and cholesterol in heart failure. Eur J Heart Fail 2001; 9:381–387.
46. The CASCADE Investigators. Randomized antiarrhythmic drug therapy in survivors of cardiac arrest (the CASCADE study). Am J Cardiol 1993; 72:280287.
47. Julian DG, Camm AJ, Frangia G, Janse MJ, Munoz A, Schwartz PJ, Simon P. Randomized trial of effect of amiodarone on mortality in patients with left ventricular dysfunction after recent myocardial infarction(EMIAT). Lancet 1997; 349:667–674.
48. Cairns JA, Connolly SJ, Roberts R, Gent M. Randomized trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarization (CAMIAT). Lancet 1997; 349:675–682.
49. Antman EM, Beamer AD, Cantillon C, et al. Therapy of refractory symptomatic atrial fibrillation and atrial flutter; a staged care approach with new antiarrhythmic drugs. J Am Coll Cardiol 1990; 15:698–707.
50. Reiffel JA, Correira J. “In the absence of structural heart disease” what is it and why does it matter as regards antiarrhythmic drug therapy? Am Heart J 1994; 128:626–629.
51. Reiffel JA. The impact of structural heart disease on the selection of class III antiarrhythmics for atrial fibrillation and flutter. Am Heart J 1998; 135:551556.
52. The CAST Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction [special report]. N Engl J Med 1989; 32:406–412.
53. Teo KK, Yusus S, Furberg CD. Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction: an overview of results from randomized controlled trials. JAMA 1993; 270:1589–1595.
54. Prystowsky EN. Inpatient versus outpatient initiation of antiarrhythmic drug therapy for patients with supraventricular tachycardia. Clin Cardiol 1994; 98: II-7-II-10.
55. Hughes MM, Trohman RG, Simmons TW, Castle LW, Wilkoff BL, Morant VA, Maloney JD. Flecainide therapy in patients treated for supraventricular tachycardia with near normal left ventricular function. Am Heart J 1992; 123:408–412.
56. Reiffel JA, Appel G. Importance of QT interval determination and renal function assessment during antiarrhythmic drug therapy. J Cardiovasc Pharmacol Ther 2001; 6:111–119.
57. Reiffel JA. Is it rationale, reasonable or excessive, and consistently applied? One view of the increasing FDA emphasis on safety first for the release and use of antiarrhythmic drugs for supraventricular arrhythmias. J Cardiovasc Pharmacol Ther 2001; 6:333–339.
58. Kassotis J, Costeas C, Blitzer M, Reiffel JA. Rhythm management in atrial fibrillation with a primary emphasis on pharmacologic—part 3. Pacing Clin Electrophysiol 1998; 21:1133–1145.
59. Julian DG, Prescott RJ, Jackson FS, Szekely P. Controlled trial of sotalol for one year after myocardial infarction. Lancet 1982; 1:1142–1147.
60. Torp-Pedersen C, Moller M, Bloch-Thomsen PE, et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. N Engl J Med 1999; 341:857–865.
61. The ALIVE Trial Investigators. The ALIVE Trial. Presented at the Annual Scientific sessions of the American College of Cardiology, 2002.
62. Doval HC, Nul DR, Grancelli HO, Varini SD, Soifer S, Corrado G, Dubner S, Scapin O, Perrone SV. Randomized trial of low-dose amiodarone in severe congestive heart failure. Lancet 1994; 344:493–498.
63. Singh SN, Fletcher RD, Fisher SG, Singh BN, Lewis HD, Deedwania P, Massie BM, Colling C, Lazzeri D. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. N Engl J Med 1995; 333:77–82.
64. Reiffel JA. Drug choices in the treatment of atrial fibrillation. Am J Cardiol 2000; 85:12D-19D.
65. Reiffel JA. Issues in the use of generic antiarrhythmic drugs. Curr Opin Cardiol 2001; 16:23–29.
66. Reiffel JA. Formulation substitution and other pharmacokinetic variability: underappreciated variables affecting antiarrhythmic efficacy and safety in clinical practice. Am J Cardiol 2000; 85:46D-52D.
67. Reiffel JA. Inpatient versus outpatient antiarrhythmic drug initiation: safety and cost-effectiveness issues. Curr Opin Cardiol 2000; 15:7–11.
68. Marcus FI. Risks of initiating therapy with sotalol for treatment of atrial fibrillation. J Am Coll Cardiol 1998; 32:177–180.